Aimmune Therapeutics (AIMT)

Aimmune Therapeutics UK Limited • Aimmune Therapeutics (Bermuda) Ltd. • Aimmune Therapeutics Netherlands B.V. • Aimmune Therapeutics Ireland Limited • Aimmune Therapeutics Germany GmbH ...

AIMT stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

15-12B

Securities registration termination

23 Oct 20

8-K

Termination of a Material Definitive Agreement

19 Oct 20

EFFECT

Notice of effectiveness

15 Oct 20

EFFECT

Notice of effectiveness

15 Oct 20

S-8 POS

Registration of securities for employees (post-effective amendment)

13 Oct 20

S-8 POS

Registration of securities for employees (post-effective amendment)

13 Oct 20

S-8 POS

Registration of securities for employees (post-effective amendment)

13 Oct 20

POS AM

Prospectus update (post-effective amendment)

13 Oct 20

S-8 POS

Registration of securities for employees (post-effective amendment)

13 Oct 20

S-8 POS

Registration of securities for employees (post-effective amendment)

13 Oct 20

Latest ownership filings

View all

SC 13G/A

Palo Alto Investors LP

16 Feb 21

Change in insider ownership

Jayson Donald Alexander Dallas

Stacey Denenberg Seltzer

14 Oct 20

ERIC BJERKHOLT

14 Oct 20

Financial summary

Financial statements Chart AIMT financial data

Quarter (USD)	Jun 20	Mar 20	Sep 19	Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	266.56 mm	266.56 mm	266.56 mm	266.56 mm	266.56 mm	266.56 mm
Cash burn (monthly)	10.62 mm	(no burn)	22.97 mm	23.59 mm	18.37 mm	18.66 mm
Cash used (since last report)	595.56 mm	n/a	1.29 bn	1.32 bn	1.03 bn	1.05 bn
Cash remaining	-329.00 mm	n/a	-1.02 bn	-1.06 bn	-763.61 mm	-779.99 mm
Runway (months of cash)	-31.0	n/a	-44.5	-44.8	-41.6	-41.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

AIMT institutional ownership history Ownership history

28.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3	3	–
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	18.74 mm	18.74 mm	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Nestle Health Science US	12.73 mm	$0.00	0.0%
Longitude Capital Partners II	6.01 mm	$0.00	0.0%
Societe des Produits Nestle	100.00	$0.00	0.0%

Largest transactions	Shares	Change
Nestle Health Science US	12.73 mm	0.0%
Longitude Capital Partners II	6.01 mm	0.0%
Societe des Produits Nestle	100.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.